Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients.
Frank BidarSarah HamadaMorgane GossezRemy CoudereauJonathan LopezMarie-Angelique CazalisClaire TardiveauKaren Brengel-PesceMarine MommertMarielle BuissonFilippo ContiThomas RimmeléAnne-Claire LukaszewiczLaurent ArgaudMartin CourGuillaume MonneretFabienne Venetnull nullPublished in: Annals of intensive care (2022)
Severe COVID-19 patients present with features of profound T cell exhaustion upon ICU admission which can be reversed ex vivo by rhIL-7. These results reinforce our understanding of severe COVID-19 pathophysiology and opens novel therapeutic avenues to treat such critically ill patients based of immunomodulation approaches. Defining the appropriate timing for initiating such immune-adjuvant therapy in clinical setting and the pertinent markers for a careful selection of patients are now warranted to confirm the ex vivo results described so far. Trial registration ClinicalTrials.gov identifier: NCT04392401 Registered 18 May 2020, http:// clinicaltrials.gov/ct2/show/NCT04392401.
Keyphrases
- sars cov
- recombinant human
- end stage renal disease
- coronavirus disease
- ejection fraction
- early onset
- newly diagnosed
- chronic kidney disease
- emergency department
- intensive care unit
- prognostic factors
- clinical trial
- study protocol
- randomized controlled trial
- magnetic resonance imaging
- mechanical ventilation
- intellectual disability
- positron emission tomography
- image quality
- drug induced
- phase ii
- autism spectrum disorder
- acute respiratory distress syndrome
- open label